Downregulated Expression of Hepatoma-derived Growth Factor (HDGF) Reduces Gallbladder Cancer Cell Proliferation and Invasion

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2013 Apr 24

PMID 23609195

Citations 22

Authors

Maolan Li

Jun Shen

Xiangsong Wu

Bingtai Zhang

Rui Zhang

Hao Weng

Qian Ding

Zhujun Tan

Guofeng Gao

Jiasheng Mu

Jiahua Yang

Yijun Shu

Runfa Bao

Qichen Ding

Wenguang Wu

Yang Cao

Yingbin Liu

Affiliations

Soon will be listed here.

Abstract

Hepatoma-derived growth factor (HDGF), a heparin-binding growth factor, has a wide range of biological functions, including mitogenic activity and vascular development. Recent studies demonstrated that HDGF also acted as an oncogene with aberrantly increased activity in multiple human cancers; however, little is known about the biological function of HDGF in gallbladder cancer (GBC). In this study, we focused on the clinical significance and biological functions of HDGF in GBC and found that Nuclear HDGF protein overexpression was frequently detected in GBC tissues. Patients with nuclear HDGF-positive tumors had worse overall survival than patients with HDGF-negative tumors. Furthermore, treatment of GBC lines with HDGF-targeting siRNA oligonucleotides (HDGF-siRNA) significantly reduced the proliferation of GBC-SD and SGC-996 cell lines and diminished both anchorage-independent growth on soft agar and cell migration. These data indicate that HDGF acts as a putative oncogene in GBC and could be a novel diagnostic and therapeutic target for GBC.

Citing Articles

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer.

Han S, Tian Z, Tian H, Han H, Zhao J, Jiao Y Cell Death Discov. 2023; 9(1):181.

PMID: 37301856 PMC: 10257651. DOI: 10.1038/s41420-023-01476-0.

MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and Prognosis.

Zou Y, Zhong C, Hu Z, Duan S Front Oncol. 2021; 11:743701.

PMID: 34676171 PMC: 8523946. DOI: 10.3389/fonc.2021.743701.

TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma.

Gu J, Fu W, Qian H, Gu W, Zong Y, Chen Q World J Gastroenterol. 2020; 26(25):3586-3602.

PMID: 32742128 PMC: 7366057. DOI: 10.3748/wjg.v26.i25.3586.

Downregulation of HDGF inhibits the tumorigenesis of bladder cancer cells by inactivating the PI3K-AKT signaling pathway.

Zhang C, Chang X, Chen D, Yang F, Li Z, Li D Cancer Manag Res. 2019; 11:7909-7923.

PMID: 31692549 PMC: 6710542. DOI: 10.2147/CMAR.S215341.

HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma.

Jiang H, Fu Q, Song X, Ge C, Li R, Li Z Oncol Lett. 2019; 18(5):4936-4946.

PMID: 31612005 PMC: 6781745. DOI: 10.3892/ol.2019.10812.

References

Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J . Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008; 99(11):2120-7. PMC: 11159754. DOI: 10.1111/j.1349-7006.2008.00928.x. View

Hsu S, Chen C, Liu G, Tai M, Wang J, Wu J . Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol. 2011; 107(1):101-9. DOI: 10.1007/s11060-011-0733-z. View

Bremer S, Klein K, Sedlmaier A, Abouzied M, Gieselmann V, Franken S . Hepatoma-derived growth factor and nucleolin exist in the same ribonucleoprotein complex. BMC Biochem. 2013; 14:2. PMC: 3551658. DOI: 10.1186/1471-2091-14-2. View

Huang J, Chao C, Su T, Yeh S, Chen D, Chen C . Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004; 315(4):950-8. DOI: 10.1016/j.bbrc.2004.01.151. View

Wang J, Peng S, Li J, Wang Y, Zhang Z, Cheng Y . Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009; 281(1):71-81. DOI: 10.1016/j.canlet.2009.02.020. View

Boutros C, Gary M, Baldwin K, Somasundar P . Gallbladder cancer: past, present and an uncertain future. Surg Oncol. 2012; 21(4):e183-91. DOI: 10.1016/j.suronc.2012.08.002. View

Zhou Y, Zhou N, Fang W, Huo J . Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol. 2010; 5:58. PMC: 2949719. DOI: 10.1186/1746-1596-5-58. View

Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y . Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol. 2007; 14(7):2141-9. DOI: 10.1245/s10434-007-9369-9. View

Li M, Wang X, Tan Z, Dong P, Gu J, Lu J . Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis. Int J Immunopathol Pharmacol. 2013; 25(4):955-65. DOI: 10.1177/039463201202500413. View

10.

Ren H, Chu Z, Mao L . Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009; 8(5):1106-12. PMC: 2933960. DOI: 10.1158/1535-7163.MCT-08-0779. View

11.

Lin Y, Li C, Chen H, Yen C, Lin L, Huang C . The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012; 48(7):629-35. DOI: 10.1016/j.oraloncology.2012.01.014. View

12.

Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y . Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006; 12(20 Pt 1):6043-8. DOI: 10.1158/1078-0432.CCR-06-1064. View

13.

Wistuba I, Gazdar A . Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004; 4(9):695-706. DOI: 10.1038/nrc1429. View

14.

Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L . Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008; 452(2):139-46. DOI: 10.1007/s00428-007-0558-5. View

15.

Kung M, Tsai H, Hu T, Kuo H, Liu L, Chen S . Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2012; 425(2):169-76. DOI: 10.1016/j.bbrc.2012.07.060. View

16.

Chen S, Kung M, Hu T, Chen H, Wu J, Kuo H . Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition. J Pathol. 2012; 228(2):158-69. DOI: 10.1002/path.3988. View

17.

Sasaki Y, Negishi H, Idogawa M, Yokota I, Koyama R, Kusano M . p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res. 2011; 71(22):7038-47. DOI: 10.1158/0008-5472.CAN-11-1053. View

18.

Meng J, Xie W, Cao L, Hu C, Zhe Z . shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 2010; 42(1):52-7. DOI: 10.1093/abbs/gmp102. View

19.

Chen X, Yun J, Fei F, Yi J, Tian R, Li S . Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract. 2012; 208(8):437-43. DOI: 10.1016/j.prp.2012.03.004. View

20.

Liao F, Dong W, Fan L . Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med Oncol. 2009; 27(4):1219-26. DOI: 10.1007/s12032-009-9362-1. View